JQ1, the first developed BET inhibitor, could efficiently suppress the expression of MYCN in neuroblastoma by inhibiting the binding of BRD4 with acetyl lysine of histone (Delmore et al., 2011). This evidence concerns the gene BRD4 and neuroblastoma.